Treatment Information

Back

Melanoma treatment details. Chemotherapy.

University of Nottingham, Nottingham, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:5City/State/Province:Nottingham
Treatments:ChemotherapyHospital:University of Nottingham
Drugs:Journal:Link
Date:May 2011

Description:

Patients:
This phase III study involved stage IV melanoma patients who were divided into two separate treatment groups. Group A included 429 patients, 64% of whom were over the age of 65 years and 58% were male. Group B had 430 patients, 61% of whom were over the age of 65 years and 59% were male.

Treatment:
Patients in group A were treated with the chemotherapy agent temozolomide. Patients in group B were given the chemotherapy agent dacarbazine.

Toxicities:
Deaths due to adverse events were reported for both groups (6 in group A and 7 in group B), but it was mentioned that they were not attributed to treatment. Grade 3-4 neutropenia, lymphopenia, thrombocytopenia, fatigue, and vomiting were also reported for both groups.

Results:
The reported median overall survival for groups A and B was 9.1 and 9.4 months, respectively.

Support:
This study was supported by the pharmaceutical company Schering Plough.

Correspondence: Dr. Poulam M. Patel; email: [email protected]



Back